跳至主要内容
临床试验/NCT00497536
NCT00497536已完成4 期

Pharmacokinetics of Insulin Aspart (IAsp) Following Continuous Subcutaneous Insulin Infusion (CSII) in Patients With Type 1 Diabetes Mellitus (T1DM)- Basal Rate Resolution.

University of Aarhus1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2007年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
12
试验地点
1
主要终点
CV SSPIasp

研究概览

简要总结

The primary objective of the study is to compare SSPIAsp during CSII giving one bolus per hour compared with multiple boluses per hour.

The secondary objective is to compare SSPIAsp during continuous subcutaneous insulin infusion (CSII) versus continuous intravenous insulin infusion (CIII).

详细描述

Rapid acting insulin, like insulin aspart, can be administered as CSII. The insulin can be administered as a basal rate with additional insulin administration from the pump related to mealtimes.

Insulin is physiologically secreted in a pulsate manner from the pancreatic β-cells with a period of 5-10 minutes, and this is responsible for plasma insulin oscillations with similar frequency. The oscillatory pattern is believed to optimize control mechanisms of insulin to enhance its action on metabolism.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Type 1 diabetes mellitus (T1DM)
  • Insulin pump users' ≥ 48 hours, 24 h dose < 80 U
  • Insulin dose ≥ 0,4 IE/kg/24hours
  • 18 years < age < 50 years
  • Time since diagnosis of T1DM ≥ 5 years
  • HbA1c ≤ 8,5 %
  • Safe anticonceptive for fertile women
  • Being able to understand and read Danish

排除标准

  • Dysregulation of endocrine disorders other than type 1 diabetes mellitus
  • Severe dysregulation of diabetes mellitus
  • Other severe adverse disease
  • Pregnancy, planning pregnancy, or nursing

研究组 & 干预措施

1

Active Comparator

≈ bolus protocol.

干预措施: Insulin Aspart (IAsp) (Drug)

2

Active Comparator

≈ CSII protocol

干预措施: Insulin Aspart (IAsp). (Drug)

3

Active Comparator

≈ CIII protocol.

干预措施: Insulin Aspart (IAsp) (Drug)

结局指标

主要结局

CV SSPIasp

时间窗: 6 hours

次要结局

  • • Δ SSPIAsp (S.C. /I.V.) • AUC IAsp • Tmax IAsp • Cmax IAsp - Bioequivalence of Iasp under SS (GIR, S-FFA, S-glycerol)(6 hours)

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验